Chronic Lymphocytic Leukemia Clinical Trial
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia
B-cell non-Hodgkin lymphoma (NHL) including RT and transformed FL, that warrants systemic therapy
Chronic Lymphocytic Leukemia (leukemia-cll/" >CLL), that warrants systemic therapy as defined by iwCLL (Hallek 2018)
NHL subjects: relapsed to or refractory after at least two prior standard systemic therapies (excluding antibiotics)
RT subjects: must have relapsed after or be refractory to at least two prior line of therapy for CLL/SLL or RT
CLL subjects: relapsed to or refractory after at least two prior standard therapies
Measurable disease defined as:
NHL (including SLL): at least 1 measurable disease lesion > 1.5 cm
CLL: at least 1 measurable disease lesion
Prior therapy with any agent blocking the CD47/SIRPα pathway or any previous CD19 targeting therapy,
Subjects receiving cancer therapy (i.e. chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) or any investigational drug within 21 days of Day 1 of Cycle 1
Prior autologous SCT within 6 months.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Fayetteville Arkansas, 72703, United States
Hackensack New Jersey, 07601, United States
Chattanooga Tennessee, 37404, United States
Nashville Tennessee, 37203, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.